Posted 30 January, 2007 - 12:54 by steve
The main source of Streptococcus suis is pig across the world.It can be spread from sick or carrier pig to human who has a close contact with it.The organism causes meningitis, septicaemia, endocarditis, arthritis, and septic shock in both hosts and mortality is high. REF:
[url=http://www.thelancet.com/journals]http://www.thelancet.com/journals[/url]
Posted 9 January, 2007 - 14:31 by steve
Many consider that Proton pump inhibitors (PPIs) may interfere with calcium absorption through induction of hypochlorhydria but they also may reduce bone resorption through inhibition of osteoclastic vacuolar proton pumps.After doing the controlled trial on 13 556 hip fracture cases and 135 386 controls, conculstion is "Long-term PPI therapy, particularly at high doses, is associated with an increased risk of hip fracture."
Full article @ http://jama.ama-assn.org/cgi/content/abstract/296/24/2947
Posted 9 January, 2007 - 14:25 by steve
[b]Effects of Continuing or Stopping Alendronate After 5 Years of Treatment[/b]
Women who discontinued alendronate after 5 years showed a moderate decline in BMD and a gradual rise in biochemical markers but no higher fracture risk other than for clinical vertebral fractures compared with those who continued alendronate. These results suggest that for many women, discontinuation of alendronate for up to 5 years does not appear to significantly increase fracture risk. However, women at very high risk of clinical vertebral fractures may benefit by continuing beyond 5 years.
Full Article on JAMA @
http://jama.ama-assn.org/cgi/content/abstract/296/24/2927
Posted 23 December, 2006 - 23:55 by steve
Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, has been shown to benefit patients with a variety of cancers.Recent study shows that the addition of bevacizumab to paclitaxel plus carboplatin in the treatment of selected patients with non–small-cell lung cancer has a significant survival benefit with the risk of increased treatment-related deaths.Source
Posted 23 December, 2006 - 23:51 by steve
In this large community-based gastroenterology practice, we observed greater rates of detection of adenomas among endoscopists who had longer mean times for withdrawal of the colonoscope. The effect of variation in withdrawal times on lesion detection and the prevention of colorectal cancer in the context of widespread colonoscopic screening is not known. Ours was a preliminary study, so the generalizability and implications for clinical practice need to be determined by future studies. Source
Posted 13 December, 2006 - 04:40 by steve
The Heart Protection Study established that statins should be used to treat cardiovascular risk, not just to lower cholesterol in people in whom it was over a certain point. This cost-effectiveness analysis from the same study comes up with prices for saving hearts and minds with simvastatin. For most of the people currently treated with statins, the drugs actually seem to save money - for those whose cardiovascular risk is too low to make them a currently indicated treatment, the cost per life year saved still comes out at a remarkably low figure (less than £2500 here). What we don't know, and can't really extrapolate so easily from the Heart Protection Study, is whether people whose age and risk are so low should actually be on statins at all. Full article
Posted 28 November, 2006 - 05:31 by steve
It is also called Heterotopic Heart Transplant.
The story source Thank you
Picture source Thank you.
Its ECG pattern can be seen on ECG Library
Posted 28 November, 2006 - 02:11 by steve
SAFE study reveals :The outcomes of resuscitation with albumin and saline are similar irrespective of patients' baseline serum albumin concentration.
http://www.bmj.com/cgi/content/abstract/333/7577/1044
Posted 28 November, 2006 - 02:07 by steve
In patients with euvolemic or hypervolemic hyponatremia, tolvaptan, an oral vasopressin V2-receptor antagonist, was effective in increasing serum sodium concentrations at day 4 and day 30.
http://content.nejm.org/cgi/content/abstract/355/20/2099
Posted 28 November, 2006 - 02:04 by steve
The use of a target hemoglobin level of 13.5 g per deciliter (as compared with 11.3 g per deciliter) was associated with increased risk and no incremental improvement in the quality of life
This trial made the national papers, not because it fell into the journalist's favourite category of Breakthrough Miracle Cure, but into their second of Killer Drug Used by Doctors. An open-label trial of 1432 patients, in whom erythropoietin was used to raise haemoglobin to above 13.5 g/dl in 715 and over 11.3 in the others, led to an increase in the primary endpoint (of death, stroke, heart attack or hospitalization with heart failure) in those bumped up to the higher haemoglobins. So complete correction of anaemia appears to be harmful, and there's a poverty of evidence regarding correction to lower levels.
http://content.nejm.org/cgi/content/abstract/355/20/2085
